The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of teclistamab in patients (pts) with heavily pretreated, relapsed/refractory multiple myeloma (RRMM), including those refractory to penta RRMM and BCMA (B-cell maturation antigen) directed therapy (BDT).
 
Priyanka Venkatesh
No Relationships to Disclose
 
Shebli Atrash
Honoraria - Janssen
Research Funding - Amgen; Celgene/Bristol-Myers Squibb (Inst); GlaxoSmithKline; Janssen Oncology (Inst); Karyopharm Therapeutics
 
Barry Paul
Consulting or Advisory Role - Celgene/Bristol-Myers Squibb; Janssen Oncology
Research Funding - Bristol-Myers Squibb/Celgene
 
Omar Alkharabsheh
Consulting or Advisory Role - Agios; Amgen; AstraZeneca; Daiichi Sankyo; Genentech; NCODA
Research Funding - Celgene/Bristol-Myers Squibb (Inst); Loxo/Lilly (Inst); Seagen (Inst)
 
Aimaz Afrough
No Relationships to Disclose
 
Zahra Mahmoudjafari
Honoraria - Bristol Myers Squibb Foundation; Incyte; Merck; Omeros; SeaGen
Speakers' Bureau - Omeros
 
Muhammad Umair Mushtaq
No Relationships to Disclose
 
Hamza Hashmi
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Janssen; Sanofi
 
James A. Davis
No Relationships to Disclose
 
Al-Ola A. Abdallah
No Relationships to Disclose